Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options. Learn more: https://www.adcentrx.com/
Location: United States, California, San Diego
Total raised: $38M
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| 27.04.2023 | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.04.2023 | Series A | $38M | - |
Mentions in press and media 12
| Date | Title | Description |
| 10.09.2024 | The New Era of Project Optimus: Implications for Oncology Development Strategy, Upcoming Webinar Hosted by Xtalks | catalystcr.com/oncology-cro In this free webinar, learn about the Project Optimus initiative for dose optimization in early-phase oncology drug development. Attendees will learn how it has impacted early-phase oncology study designs. The fe... |
| 06.12.2023 | Adcentrx Extends Series A+ Financing to $51M | Adcentrx Therapeutics, a San Diego, CA- and Shanghai, China-based biotechnology company dedicated to developing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, extended ints Series A+ financing to ... |
| 05.12.2023 | Adcentrx extends Series A+ Funding to $51M to boost development of portfolio programs | - |
| 25.04.2023 | Our investment in Adcentrx Therapeutics | Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing. ... |
| 25.04.2023 | Adcentrx Therapeutics Closes $38M Series A+ | SAN DIEGO, CA, Adcentrx Therapeutics announces the closing of a $38 million Series A+ financing. >> Click here for more funding data on Adcentrx Therapeutics >> To export Adcentrx Therapeutics funding data to PDF and Excel, ... |
| 25.04.2023 | Adcentrx Therapeutics closes $38M Series A round to advance their proprietary therapeutic pipeline | - |
| 25.04.2023 | Adcentrx Therapeutics Closes $38M Series A+ Financing | Adcentrx Therapeutics, a San Diego, CA and Shangai, China-based biotechnology company dedicated to advancing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, closed a $38m Series A+ financing. The r... |
| 25.04.2023 | Adcentrx Therapeutics Raises $38M | San Diego-based Adcentrx Therapeutics, a biotech company which is focused on treatments for cancer and other diseases, has raised $38M in a Series A+ funding round. The company said the funding was led by Eight Roads Ventures, and also incl... |
| 24.04.2023 | Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures | - |
| - | Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development | SHANGHAI and SAN DIEGO, Calif., April 28, 2021 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development,... |
Show more